North America’s medical devices industry saw a rise of 42.86% in cross border deal activity during December 2020, when compared with the last 12-month average, led by Koninklijke Philips ‘ $2.8bn acquisition of BioTelemetry, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 20 medical devices industry cross border deals worth $4.79bn were announced for the region in December 2020, against the 12-month average of 14 deals.

Of all the deal types, venture financing saw most activity in December 2020 with ten transactions, representing a 50% share for the region.

In second place was M&A with eight deals, followed by private equity deals with two transactions, respectively capturing a 40% and 10% share of the overall cross border deal activity for the month.

In terms of value of cross border deals, M&A was the leading category in North America’s medical devices industry with $3.52bn, while private equity and venture financing deals totalled $772.47m and $500.19m, respectively.

North America medical devices industry cross border deals in December 2020: Top deals

The top five medical devices cross border deals accounted for 88% of the overall value during December 2020.

The combined value of the top five medical devices cross border deals stood at $4.21bn, against the overall value of $4.79bn recorded for the month.

The top five medical devices industry cross border deals of December 2020 tracked by GlobalData were:

1) Koninklijke Philips’ $2.8bn acquisition of BioTelemetry

2) The $700m private equity deal with Verily Life Sciences by Alphabet, Ontario Teachers’ Pension Plan, Silver Lake Partners and Temasek Holdings (Private)

3) Richter Gedeon Nyrt’s $263.5m asset transaction with Janssen Pharmaceutica

4) The $250m acquisition of EmendoBio by AnGes

5) Baillie Gifford, Franklin Templeton Investments , Google , Novo Holdings and T Rowe Price Associates ‘ venture financing of Tempus Labs for $200m.